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Abstract: Tumor growth is associated with oxidative stress, which causes lipid peroxidation. The most
intensively studied product of lipid peroxidation is 4-hydroxy-2-nonenal (HNE), which is considered
as a “second messenger of free radicals” that binds to proteins and acts as a growth-regulating signaling
factor. The incidence of squamous cell carcinoma of the oropharynx is associated with smoking,
alcohol and infection of human papilloma virus (HPV), with increasing incidence world-wide.
The aim of this retrospective study involving 102 patients was to determine the immunohistochemical
appearance of HNE-protein adducts as a potential biomarker of lipid peroxidation in squamous
cell carcinoma of the oropharynx. The HNE-protein adducts were detected in almost all tumor
samples and in the surrounding non-tumorous tissue, while we found that HNE is differentially
distributed in squamous cell carcinomas in dependence of clinical stage and histological grading of
these tumors. Namely, the level of HNE-immunopositivity was increased in comparison to the normal
oropharyngeal epithelium in well- and in moderately-differentiated squamous cell carcinoma, while
it was decreasing in poorly differentiated carcinomas and in advanced stages of cancer. However,
more malignant and advanced cancer was associated with the increase of HNE in surrounding,
normal tissue. This study confirmed the onset of lipid peroxidation, generating HNE-protein adducts
that can be used as a valuable bioactive marker of carcinogenesis in squamous cell carcinoma of
the oropharynx, as well as indicating involvement of HNE in pathophysiological changes of the
non-malignant tissue in the vicinity of cancer.
Keywords: 4-Hydroxy-2-nonenal (HNE); immunohistochemistry; lipid peroxidation; oxidative stress;
protein modifications; monoclonal antibodies; squamous cell carcinoma; oropharynx
1. Introduction
Oxidative stress (OS) is the process of excessive production of reactive oxygen species (ROS),
notably of free radicals, playing a major role in the etiology of major human diseases, including cancer.
It occurs when the anti-oxidative capacities of cells and tissues are in disbalance with ROS, which causes
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oxidative damage of cells. In equilibrium, free radicals are neutralized and removed by enzymatic
and nonenzymatic antioxidants [1]. Excessive production of ROS induces lipid peroxidation (LPO),
especially of omega-6-polyunsaturated acids, which evolves as the autocatalytic process generates
highly reactive aldehydes, notably 4-hydroxy-2-nonenal (HNE), malondialdehyde (MDA) and acrolein
(Figure 1) [2,3]. The most intensively studied product of lipid peroxidation is HNE, which is considered
to be “the second messenger of free radicals” that affects pathophysiology of cells in various ways.
High concentrations of HNE are cytotoxic and mutagenic, while in physiological processes, present at
low levels, HNE acts as a signaling molecule involved in growth regulation, interacting with cytokines
and regulating the expression of cellular (proto)oncogenes [2,4,5]. The cytotoxic effects of reactive
aldehydes resemble the toxicity of ROS, but because of their higher chemical stability, these aldehydes
can spread from the site of origin and react with major biomolecules, among which proteins appear
to be the major target, even at the distant site. Because of high reactivity with biomolecules and its
multiple biological effects, HNE is a popular LPO product in the field of molecular oncology.
Carcinogenesis is a multistep process, and its etiology is still not completely understood. During
the past decade, permanent oxidative damage caused by overproduction of ROS and consequent
biomolecular damage has been proposed to play important roles in both initiation and in promotion
of cancer development [6,7]. Considering the complexity of mechanisms of carcinogenesis and of
oxidative stress, cancer may be considered both as a cause and as a consequence of oxidative stress.
Malignant alteration is a long-term process from normal to neoplastic cell, during which many
intracellular molecular mechanisms occur, changing the structure and function of specific tumor
suppressor genes or proto-oncogenes, which are also affected by HNE [8].
Oropharyngeal carcinoma refers to cancer of the tonsil, base and posterior one-third of the tongue,
soft palate, and posterior and lateral pharyngeal walls. Squamous cell carcinoma (SCC) comprises
over 95% of oropharyngeal cancers [9]. As its incidence is increasing, squamous oropharyngeal cancer
makes 10% of all head and neck cancers or more than 52,000 new cases annually worldwide [10].
Although oropharyngeal cancer is more common among elderly people, in recent years, patients with
oropharyngeal cancer have been diagnosed younger and more commonly female as human papilloma
virus (HPV) infection has emerged as an important factor of its etiology [11]. Genetic predisposition
also plays an important role in oropharyngeal carcinogenesis [12], while people who both drink
and smoke heavily have 30 times more risk for developing oropharyngeal cancer. According to the
recent World Health Organization (WHO) classification, oropharyngeal cancers can be divided into
two types, HPV-positive, which are related to human papilloma virus infection, and HPV-negative
cancers, which are usually linked to alcohol or tobacco use [13]. Hence, a genetic predisposition may
occur as a consequence of increased mutagen sensitivity, or an inability to metabolize carcinogens or
pro-carcinogens, or to repair the DNA damage [14].
Squamous cell cancer arises from a multilayered squamous epithelium or from a cylindrical
epithelium after squamous cell metaplasia. Invasive growth is manifested by invasion of the basal
membrane and infiltration of underlying tissue, blood vessels and nerves [15]. According to the World
Health Organization (WHO), on the basis of the amount of keratin formation and the morphological
appearance of the cell, squamous cell carcinoma is divided into three grades: Grade I —well
differentiated, Grade II—moderately well differentiated, and Grade III—poorly differentiated epithelial
neoplasm. Surface epithelium close to invasive cancer often shows premalignant changes likely to be
caused by the same carcinogens [16]. The majority of tumors of the oropharynx reveal themselves
most often in the late stages of the disease with metastases in the regional lymph nodes of the neck.
Patients who do not have affected lymph nodes at the time of diagnosis have an excellent prognosis
while patients with affected lymph nodes have 50% less chance of 5-year survival regardless of the
treatment applied [17]. Progress in understanding the genetic and molecular basis of cancer has led to
the research and discovery of specific changes in oropharyngeal squamous cell carcinoma that help
prevention, timely diagnosis and adequate treatment [13,18].
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Figure 1. Generation of HNE as a product of lipid peroxidation. (A) Due to the attack of oxygen free 
radical X. (mostly hydroxyl radical) on the omega-6-poylunsaturade acids (PUFA), the chain-
reaction of lipid peroxidation is initiated. (B) Lipid hydroperoxides can be spontaneously or under 
the influence of transition metals further metabolized generating radicals themselves. (C) The end 
products of oxidative degradation of PUFA are reactive aldehydes, among which HNE exhibits the 
most prominent biochemical and biomedical effects, acting as a second messenger of free radicals. 
(D) In the case of the presence of lipid-soluble antioxidants, the initial stage of lipid peroxidation 
can be terminated. 
Carcinogenesis is a multistep process, and its etiology is still not completely understood. 
During the past decade, permanent oxidative damage caused by overproduction of ROS and 
consequent biomolecular damage has been proposed to play important roles in both initiation and 
in promotion of cancer development [6,7]. Considering the complexity of mechanisms of 
carcinogenesis and of oxidative stress, cancer may be considered both as a cause and as a 
consequence of oxidative stress. Malignant alteration is a long-term process from normal to 
neoplastic cell, during which many intracellular molecular mechanisms occur, changing the 
Figure 1. Generation of HNE as a product of lipid peroxidation. (A) Due to the attack of oxygen free
radical X. (mostly hydroxyl radical) on the omega-6-poylunsaturade acids (PUFA), the chain-reaction
of lipid peroxidation is initiated. (B) Lipid hydroperoxides can be spontaneously or under the influence
of transition metals further metabolized generating radicals themselves. (C) The end products of
oxidative degradation of PUFA are reactive aldehydes, among which HNE exhibits the most prominent
biochemical and biomedical effects, acting as a second messenger of free radicals. (D) In the case of the
presence of lipid-soluble antioxidants, the initial stage of lipid peroxidation can be terminated.
Compl x roles of LPO i human carcinoge esis are still not sufficiently understoo . Namely,
LPO is generally considered to be an undesirable process of oxidative stress, which results not only in
destruction of the lipids attacked by ROS, but also in generation of their cytotoxic and carcinogenic
end-products, especially in the case of the LPO of omega-6-polyunsaturated fatty acids (PUFAs).
Thus, recent immunohistochemistry studies have implied that LPO products like HNE and acrolein
can serve even as prognostic factors [19,20]. This might be due to the concentration-dependent
cytotoxic and growth regulating effects of HNE on one side and on the other on its involvement
in inflammation in the tumor itself and in the surrounding non-tumor tissue [21]. The occurrence
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of HNE as the final product of lipid peroxidation in tumors has been well described especially for
glial tumors [22]. Immunohistochemical positivity of HNE was shown to be present in astrocytic,
oligodendroglial and ependymal tumors, while its expression was gradually increasing in tumor cells
with higher grade and neovascularization, which can be explained by the high concentration of PUFAs,
the major source of HNE in blood vessels and in cellular lipid biomembranes. In malignant variants
of glial tumors, the HNE immunopositivity was moderate to strong and was diffusely distributed in
tumor tissue. The HNE was expressed in endothelium and vascular walls of almost all tumor vessels
and it was increased with the grade of malignancy. These findings suggest that LPO is a common
process in all glial tumors generating that an increase of HNE may be associated with malignancy
and neovascularization [23]. Similarly, a retrospective study of patients with breast cancer has shown
the expression of HNE as the strongest in invasive breast carcinomas, while 8-OHdG expression
diminished in invasive breast carcinomas compared to non-invasive carcinomas [24]. In kidney cancer,
the immunopositivity of HNE was observed in cytoplasm of tumor cells but without correlation with
the clinical stage of the disease, while in healthy non-malignant kidney cells, HNE-protein adducts
were not found [25].
In the studies on involvement of ROS and HNE in carcinogenesis of colorectal cancer, there are
contradictory findings. Kondo et al. found a positive correlation between HNE expression and disease
progression [26], while Biasi and her group found significantly reduced HNE expression in colon cancer
tissue compared with non-malignant colon tissue, but not in the advanced stages of the disease [27].
Since non-malignant colon tissue used by Biasi et al. was obtained from patients with Crohn’s
disease, immunohistochemical findings of human colon carcinoma require better understanding of the
pathophysiology of HNE in cancer and its association with chronic inflammation.
The aim of this retrospective study was to analyze the appearance of HNE-protein adducts in
oropharyngeal squamous cell carcinoma and to confirm the assumed onset of oxidative stress and lipid
peroxidation in its carcinogenesis. To date, no research has been published on possible involvement of
HNE in cancer development in this field, hence, the results take another step forward in understanding
this particular malignant disease with increasingly raising incidence.
2. Results
The study included 102 patients operated on for oropharyngeal squamous cell carcinoma.
The intensity and distribution of HNE-protein adducts in tumors and in non-tumorous oropharyngeal
tissue were studied. The presence of HNE-protein adducts in tumor cells (Table 1, Figure 2) was
detected in almost all samples (99/102), confined mostly to the cytoplasm of cancer cells.
Table 1. Semiquantitative analysis of the HNE-immunopositivity and intensity of immunochemical
reaction in malignant cells.
HNE-
Immunopositivity
Cytoplasm of Tumor Cell Nuclei of Tumor Cell
No. of
Specimens/Patients
Intensity of
Immunostaining *
No. of
Specimens/patients
Intensity of
Immunostaining*
0 3 - 69 -
1 5 50 17 9
2 8 40 4 16
3 86 8 12 8
Legend: ′0′ negative—cancer cells were not positive for HNE, ′1′ HNE-immunopositivity was observed in less
than 25% of tumor cells, ′2′—immunopositivity was observed in 25–50% tumor cells, ′3′ immunopositivity was
observed in more than 50% of cancer cells; *—according to the brown color developed using 3, 3,-diaminobenzidine
(DAB) chromogen.
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Figure 2. The immunohistochemical appearance of HNE in squamous cell carcinoma of the 
oropharynx. (A) Control staining without monoclonal antibody against HNE-protein adducts 
(consequently there is no brown chromogen reaction of DAB). (B) The appearance of the HNE-
modified proteins mostly in cytoplasm of tumor cells of carcinoma grade I expressed at low staining 
intensity presented as yellow/light brown color (low magnification). (C) The appearance of the 
HNE-modified proteins carcinoma of the grade III mostly in cytoplasm and in some nuclei of tumor 
cells present as low to moderate intensity (some examples are indicated by small black arrows). 
Surrounding stroma is negative for HNE (indicated by asterisk), while chronic inflammatory cells, 
presented as dark spots, show presence of HNE (high magnification). (D) The appearance of HNE-
modified proteins in another tumor of grade III but with moderate to high intensity of 
immunostaining. Surrounding stroma and chronic inflammatory cells (indicated by big red arrows) 
also show the presence of HNE. 
The nuclei of cancer cells were mostly negative for HNE (69/102), while in the case of positive 
immunostaining its intensity was very strong and frequently present in cancer cells of only eight 
patients, i.e., in the same specimens that were also expressing the highest immunopositivity of the 
cytoplasm of malignant cells. 
The presence of HNE-protein adducts in the normal cells within tumor and surrounding tissue 
is presented in Figure 3 and Table 2. 
Figure 2. The immunohistochemical appe rance of HNE in squamous cell carcinoma of the ropharynx.
(A) Control staining with ut monoclonal antibody agai st HNE-protein adducts (conseque tly there
is no brown chromogen reaction of DAB). (B) The appearance of the HNE-modified proteins mostly
in cytoplasm of tu or cells of carcinoma grade I expressed at low staining intensity presented as
yellow/light brown color (lo magnification). (C) The appearance of the HNE-modified proteins
carcinoma of the grade III mostly in cytoplasm and in some nuclei of tumor cells present as low to
moderate intensity (some examples are indicated by s all black arrows). Surrounding stroma is
negative for HNE (indicated by asterisk), while chronic inflammatory cells, presented as dark spots,
show presence of HNE (high magnification). (D) The appearance of HNE-modified proteins in another
tumor of grade III but with moderate to high intensity of immunostaining. Surrounding stroma and
chronic inflammatory cells (indicated by big red arrows) also show the presence of HNE.
The HNE-immunopositivity was semi-quantitatively graded as +1 in 5 samples, +2 in 8 samples
and +3 in 86 samples (according to the incidence of immunopositive cells), while immunostaining
of low intensity was found in 50 samples, moderate intensity in 40 samples and strong intensity in
9 samples (according to the brown color appearance upon the DAB staining). Interestingly, even in
patients whose cancer cells were mostly immunopositive for HNE, only a few had strong intensity of
immunostaining (8/86).
The nuclei of cancer cells were mostly negative for HNE (69/102), while in the case of positive
immunostaining its intensity was very strong and frequently present in cancer cells of only eight
patients, i.e., in the same specimens that were also expressing the highest immunopositivity of the
cytoplasm of malignant cells.
The presence of HNE-protein adducts in the normal cells within tumor and surrounding tissue is
presented in Figure 3 and Table 2.
Mesenchymal stroma was positive for HNE in less than half of the cases (41/97), while blood
vessels (walls) were HNE-immunopositive in more than half of the cases (58/97). Opposite to that,
endothelium of blood vessels was negative for HNE in the majority of the cases (87/97). As expected, if
present, inflammatory cells, notably lymphocytes and plasma cells, contained HNE in majority of the
cases (66/79).
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Figure 3. The immunohistochemical appearance of HNE in normal, healthy oropharyngeal mucosa. 
(A) No HNE can be seen in the normal epithelium of the healthy subject (indicated by asterisk), 
although adjacent stromal tissue contains HNE (indicated by arrows). (B) Prominent presence of 
HNE in non-malignant epithelium in the vicinity of squamous cell carcinoma grade III of the 
oropharynx. 
Mesenchymal stroma was positive for HNE in less than half of the cases (41/97), while blood 
vessels (walls) were HNE-immunopositive in more than half of the cases (58/97). Opposite to that, 
endothelium of blood vessels was negative for HNE in the majority of the cases (87/97). As 
expected, if present, inflammatory cells, notably lymphocytes and plasma cells, contained HNE in 
majority of the cases (66/79). 
Table 2. The presence of HNE-immunopositivity in non-malignant tissue cells within/near tumor. 
HNE-Positivity N * 
Stromal cells 
Positive  41 
Negative  56 
Blood vessel wall 
Positive 58 
Negative 39 
Endothelium 
Positive 10 
Negative 87 
Inflammatory cells 
Positive 66 
Negative 13 
 
*—number of patients/specimens analyzed (the remaining up to 102 in total did not contain the 
respective type of cells/tissue). 
As can be seen in Figure 4, the HNE-immunopositivity in the epithelium close to carcinoma 
was elevated in non-malignant cells of all clinical stages of carcinoma in comparison to the control 
Figure 3. The immunohistochemical appearance of HNE in normal, healthy oropharyngeal mucosa.
(A) No HNE can be seen in the normal epithelium of the healthy subject (indicated by asterisk),
although adjacent stromal tissue contains HNE (indicated by arrows). (B) Prominent presence of HNE
in non-malignant epithelium in the vicinity of squamous cell carcinoma grade III of the oropharynx.
Table 2. The presence of HNE-immunopositivity in non-malignant tissue cells within/near tumor.
HNE-Positivity N *
Stromal cells
Positive 41
Negative 56
Blood vessel wall
Positive 58
Negative 39
Endothelium
Positive 10
Negative 87
Inflammatory cells
Positive 66
Negative 13
*—number of patients/specimens analyzed (the remaining up to 102 in total did not contain the respective type of
cells/tissue).
As can be seen in Figure 4, the HNE-immunopositivity in the epithelium close to carcinoma was
elevated in non-malignant cells of all clinical stages of carcinoma in comparison to the control group,
without cancer (p <0.05). A significant difference was also found for malignant cells by comparison
between stages III and IV (p = 0.038).
In non-malignant epithelial cells close to the tumor intensity of staining was higher in advanced
malignancies. Hence, a statistically significant difference was eventually found comparing the mean
values between clinical stages II and III (p = 0.042) and clinical stages II and IV (p = 0.012).
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3. Discussion
The aim of this study was to determine the immunohistochemical expression of HNE-histidine
conjugates, as biomarker of OS in squamous cell carcinoma of the oropharynx. Our findings indicate
that HNE is differentially distributed in squamous cell carcinomas in dependence of clinical stage and
histological grading of these tumors. The tonsils and the basis of the tongue represented about 90% of
all oropharyngeal squamous cell carcinomas in our study, thus resembling usual appearance of these
malignances [28,29]. The stage of the disease at the time of diagnosis is among the most accepted
prognostic factors. More than half of the patients involved in this study (61.7%) were in advanced
stages of the disease. The second prognostic factor is the histological grade of tumor differentiation
that cannot be associated with the probability of metastasis and does not show a uniform distribution
in the stage of the disease.
In our study, two out of three of the patients had moderate to poorly differentiated tumors, which
were at the advanced stages of the disease. The appearance of LPO according to the presence of
HNE-protein adducts was found in tumor cells of almost all analyzed squamous cell carcinomas.
Alongside the cancer cells, the HNE-protein adducts were found within the wall of the blood vessels,
tumor stroma and inflammatory cells of most analyzed samples.
Therefore, our findings show the onset of OS in squamous cell carcinoma of oropharynx, which is
associated with LPO and the consequent synthesis of HNE, being higher in tumor cells than in the
surrounding non-tumor epithelium and in the control samples. The level of HNE immunopositivity
increased in well and moderately differentiated squamous cell carcinoma, while it was gradually
decreasing in poorly differentiated carcinomas and in advanced stages of disease.
The presence of HNE was found at a high percentage in cytoplasm of tumor cells in all tumor
grades as well as in the surrounding epithelium close to carcinoma, while the presence of HNE in cell
nuclei was found to be in a lower percentage. In the control group, HNE positivity was found only
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in the cytoplasm of cells, whereas the nuclei in all samples were negative. By comparing the clinical
stages of disease, HNE positivity was more pronounced in cytoplasm than in nuclei in tumor cells and
fell in stage IV of disease compared to the first three stages; it was statistically significant only for stage
III of the disease. The intensity of HNE immunoreaction in the first three stages of the disease was
generally moderate; at stage IV of the disease, the intensity was only weak. At all stages of the disease,
expression of HNE in the surrounding non-tumor epithelium was positive in cytoplasm of cells in
relation to the control group, particularly in cases of stages II and IV of the disease.
The presence of HNE-protein adducts was also found in inflammatory cells, especially
macrophages, in the stroma of the tumor and around tumor. It has been observed that the level of
HNE in stroma decreased with tumor grade, while HNE-positivity in tumor stroma was stronger than
in control, healthy tissue. This can be explained by the fact that inflammatory cells produce a large
amount of ROS and thus induce lipid peroxidation. In support of this, the presence of HNE positivity
in tumor stroma and inflammatory cells was related to the presence of HNE in tumor cells depending
on the carcinoma degree. During the phagocytosis, there is an “oxidative burst” of inflammatory cells
producing ROS, causing further enhancement of OS and LPO [30]. The increase of ROS is associated
with disturbed tumor cell growth and is a homeostasis disorder that is caused either by increased
ROS generation or by reduced ROS-enzyme elimination [31]. It has been confirmed that levels of
enzymes removing ROS such as SOD, glutathione peroxidase and peroxyredoxin are significantly
impaired in malignant cells and tissue, all leading to impaired homeostasis and stress adaptation in
tumor cells [32]. This can lead to a circulus vitiosus where reactive aldehydes can be only partially
removed from the tissue. However, the accumulated HNE can cause death of the tumor cells. To avoid
that, cancer cells may contain lowers amounts of lipids and PUFAs, thus reducing the production
of HNE in the tissue [32]. This can explain the reduced amount of reactive aldehydes in advanced
stages compared with earlier stages of the disease, resembling also results obtained for the primary
hepatocarcinomas [33,34]. Such a similarity between different types of cancer is in agreement with
findings that were already obtained in the 1960s, showing that the different malignant cells express
similar patterns of altered lipid metabolism, consequently resembling each other more than resembling
their respective, non-malignant counterpart cells [35]. Therefore, it is not surprising that oropharyngeal
carcinomas analyzed in the current study are similar to findings obtained for liver cancer. The process
of liver carcinogenesis analyzed on particular strains of rats (LEC) that accumulate copper, acting as
a pro-oxidant transition metal, appears to be associated with a similar process of gradual increase
of HNE-protein adducts, which correlates to the onset of jaundice and hepatitis [36]. Interestingly,
although non-malignant cells only rarely express positive immunostaining for the HNE-protein adducts
in the nuclear part of the cells, in the case of liver carcinogenesis occurring in the LEC rats, nuclei of
some cells were HNE-positive even before jaundice, while the nuclear immunopositivity for HNE was
lost afterwards. Eventually, thus transformed hepatocarcinomas cells did not contain HNE-protein
adducts at all, while the non-malignant liver cells in their vicinity were loaded with HNE-protein
adducts [34], Therefore, we think that such dynamic changes could be responsible for the observed
differences between the onset of the HNE-immunopositivity in the cytoplasm and in the nuclei of
oropharyngeal carcinoma cells, as observed in the current study, keeping in mind that each cancer is a
specific entity and every patient is a different individual.
Similarly, the study of colon adenocarcinoma revealed the reduced presence of another lipid
peroxidation product acrolein in advanced cancer [37]. In this study, different presence of acrolein in
benign adenomas and in malignant adenocarcinomas of the colon were observed, depending on the
clinical stage of the disease and the histological tumor grade, eventually being lower in advanced than
in the earlier stages of the disease. However, the expression of acrolein was found to be abundant
in non-malignant colon epithelium surrounding advancing cancer tissue, thus resembling findings
obtained for human and murine liver malignancies [33,35]. These results should be interpreted
considering the complex pattern of HNE-metabolizing enzymes in tumor cells; the lipid composition
of the cell membranes with a different level of peroxidizable substrates in normal and in malignant
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cells (such as PUFAs); and the presence of inflammatory cells, which can increase the level of diffusible
HNE, acrolein and related lipid peroxidation products from the tumor-surrounding tissues, especially
if bound to the proteins [32].
The relevance of inflammatory cells and tumor stroma in the onset of LPO during carcinogenesis
and in the host defense against invading cancer were described both in clinical trials and experimental
models of murine cancer regression. Namely, the phenomenon of spontaneous regression of W256
murine tumors was found to be associated with pronounced oxidative bust and anticancer activities of
neutrophil granulocytes generating HNE and acrolein, resembling the effects of granulocytes and HNE
on melanoma B16 [38–40], while in patients with metastatic lung cancer the onset of inflammation
related to the invading metastatic cancer and the accumulation of HNE-protein adducts were found to
be more pronounced than in the case of primary lung cancer [41].
On the other hand, changes of lipid metabolism during carcinogenesis and cancer spread in the
organism certainly do depend also on the type of cancer, even if originating from the same organ,
reflecting high individual differences even between the same types of malignant cells, as was observed
for the human lung cancer [42]. Consequently, these will result also in a differently expressed onset of
LPO, not only on the level of the affected non-malignant tissue and cancer itself, but also on the level
of the entire organism, similarly to the other metabolic changes caused by cancer [43].
Finally, together with the above mentioned involvement of HNE in the innate immune system
anti-cancer effectiveness, a possible crucial role of HNE in the host defense against cancer might be
based on its universal regulatory activities affecting lipid metabolism and the growth of the cells on
one hand, and on the other, the selective anti-cancer effects of HNE, depending on its antioxidant,
pro-apoptotic and cytokine signaling regulation, proportional to its binding to the (extra)cellular
proteins [44–49]. Among these, recently revealed selective anticancer effects of HNE generated by the
non-malignant cells attenuating or even entirely blocking cancer-specific tumor membrane-associated
catalase, might be of particular relevance [50].
In conclusion, this study revealed the onset of OS and LPO in the development of human malignant
epithelial tumors and the immunohistochemical presence of HNE in squamous cell carcinoma of
oropharynx and in surrounding non-tumorous tissue. Our study also further supports the assumption
of HNE as a bioactive marker of OS and a potentially defensive, anti-cancer factor generated by
surrounding non-malignant cells.
4. Materials and Methods
4.1. Tumors
We analyzed 102 surgical specimens diagnosed as oropharyngeal squamous cell carcinoma at the
Department of Pathology and Cytology, University Hospital Center Zagreb, during the period 2002
to 2007. The mean age of patients was 59 years, and the group consisted of 11 females and 91 males.
The youngest participant was 21 years old, whereas the oldest one was 88 years old. They included
51 cases of tongue base carcinoma, 38 cases of tonsil carcinoma, 7 cases of posterior pharyngeal wall
carcinomas, and 6 cases of soft palate carcinoma. All the tumors were classified according to the criteria
of WHO [12] for histological grades, 27 cases of SCC grade I, 40 cases of SCC grade II, and 35 cases of
SCC grade III. For all patients, pathohistological data (tumor size, histologic type of SCC, histologic
grade, lymph node status, and distant metastasis) were obtained. Based on TNM classification, tumors
grade T1 and T2 are classified as early, while T3 and T4 are advanced. The analyzed sample included
58 early diagnosed tumors and 44 locally advanced tumors. According to American Joint Committee
on Cancer (AJCC), this study included 39 cases of early stages (stage I and II) of disease and 63 cases of
advanced (stage III and IV) stages of disease. Ethical Committee of the Clinical Hospital Centre Zagreb
approved the study under permit name “Metabolomic and pathomorphological trials in oncology”
and 02/21 AG number.
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4.2. Normal Oropharyngeal Tissue
The control group consisted of 32 samples of oropharynx mucosa tissue operated after tonsillectomy
due to chronic tonsillitis or oropharynx mucosa samples obtained according to the protocol for diagnosis
of tumors of an unknown primary location. In all control samples, histopathological examination
showed no tumor or other inflammatory and reactive changes.
4.3. Tissue Processing
All tumors used in the study were surgically resected at Department of ENT surgery, University
Hospital Center Zagreb. The specimens were fixed in 10% buffered formalin immediately after resection,
dehydrated in ethanol, and embedded in paraffin. Representative paraffin blocks of each tumor and
surrounding mucosa were cut in three 5-µ-thin slices examined by section staining with hematoxylin and
eosin and immunohistochemistry method using monoclonal antibody for HNE-histidine conjugates.
Immunohistochemical staining was performed using a monoclonal antibody for the detection of
HNE-modified proteins. It was obtained from the culture medium of the clone derived from a fusion of
Sp2-Ag8 myeloma cells with B-cells of a BALBc mouse immunized by HNE-modified keyhole limpet
hemocyane [51]. The antibody is specific for the HNE-histidine epitope in HNE-protein (peptide)
conjugates. Dilutions of antibody solution and appropriate reagents from the EnVision detection kit
(K 8000, DAKO) were used on a DAKO automated immunostainer. Antigens were localized using an
avidin-biotin method with 3, 3,-diaminobenzidine (DAB) as a chromogen, and counterstained with
hematoxylin (Kemika, Zagreb, Croatia). The immunohistochemical investigation of intensity and
distribution of HNE in the tumor and surrounding non-tumorous mucosa were determined and scored
in a semi-quantitative way (0: 0% positive cells, +1: 1–25% positive cells, +2: 26–50% positive cells, +3:
51–100% positive cells). Staining intensity was divided into three groups: low, moderate and strong.
The presence of HNE-protein adducts in specific structures like endothelial cells and walls of blood
vessels, mesenchymal stroma, and chronic inflammatory infiltrate was defined as negative (−) in the
absence of the HNE-protein adducts and as positive (+) in the presence of HNE-protein adducts. Two
pathologists diagnosed each specimen independently.
4.4. Statistical Analyses
The incidence of HNE-positive vs. HNE-negative tissues depending on the type of tumor
was evaluated by chi-square test. Possible differences in the intensity of staining were examined
by Mann-Whitney test, using a numerical description of positivity corresponding to the respective
standard grading of positivity as described above.
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